

Malignant hyperthermia

Description

Malignant hyperthermia is a severe reaction to particular anesthetic drugs that are often used during surgery and other invasive procedures. Specifically, this reaction occurs in response to some anesthetic gases, which are used to block the sensation of pain, either given alone or in combination with a muscle relaxant that is used to temporarily paralyze a person during a surgical procedure. If given these drugs, people at risk of malignant hyperthermia may experience a rapid increase in heart rate and body temperature (hyperthermia), abnormally fast breathing, muscle rigidity, breakdown of muscle fibers (rhabdomyolysis), and increased acid levels in the blood and other tissues (acidosis). Without prompt treatment and cessation of the drugs, the body's reaction can cause multiple organs to be unable to function, including the heart (cardiac arrest) and kidneys (renal failure), and it can cause a blood clotting abnormality called disseminated intravascular coagulation. These complications may be life-threatening. (In medicine, the term malignant refers to conditions that are dangerous to one's health.)

People at increased risk of this disorder are said to have malignant hyperthermia susceptibility. Affected individuals may never know they have the condition unless they have a severe reaction to anesthesia during a surgical procedure or they undergo testing (for instance, if susceptibility is suspected because a family member had a severe reaction). Malignant hyperthermia may not occur every time anesthesia is used. Many individuals who develop a severe reaction have previously been exposed to a triggering drug and not had a reaction.

Affected individuals may be at increased risk for "awake" malignant hyperthermia, in which the severe reaction occurs in response to physical activity, often while sick, rather than in reaction to exposure to a triggering drug.

While malignant hyperthermia often occurs in people without other serious medical problems, certain inherited muscle diseases (including central core disease, multiminicore disease, and STAC3 disorder) are associated with malignant hyperthermia susceptibility.

Frequency

Malignant hyperthermia occurs in 1 in 5,000 to 50,000 instances in which people are given anesthetic gases. Susceptibility to malignant hyperthermia is probably more frequent, because many people with an increased risk of this condition are never

exposed to drugs that would trigger a reaction and bring them to medical attention.

Causes

Certain variations of the *RYR1* and *CACNA1S* genes increase the risk of developing malignant hyperthermia. Mutations in the *RYR1* gene account for most cases of malignant hyperthermia susceptibility, while mutations in the *CACNA1S* gene cause less than 1 percent of all cases of malignant hyperthermia susceptibility.

The *RYR1* and *CACNA1S* genes provide instructions for making proteins that play essential roles in muscles used for movement (skeletal muscles). For the body to move normally, these muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of certain charged atoms (ions) in muscle cells. The proteins produced from the *RYR1* and *CACNA1S* genes are involved in the movement of calcium ions within muscle cells. In response to certain signals, the *CACNA1S* protein helps turn on (activate) the *RYR1* channel. When the *RYR1* channel is active, it releases calcium ions from storage into the fluid-filled space inside muscle cells. The resulting increase in calcium ion concentration inside the cells stimulates muscles to contract.

Mutations in the *RYR1* or *CACNA1S* gene cause the *RYR1* channel to open more easily and close more slowly in response to certain drugs. As a result, abnormally large amounts of calcium ions are released from storage within muscle cells. The abnormal increase in calcium ion concentration within muscle cells activates processes that generate heat (leading to increased body temperature) and produce excess acid (leading to acidosis). An overabundance of calcium ions also causes skeletal muscles to contract, which leads to muscle rigidity.

Up to half of people with malignant hyperthermia susceptibility do not have a mutation in one of the known genes. The causes of these cases are still under study.

[Learn more about the genes associated with Malignant hyperthermia](#)

- CACNA1S
- RYR1

Inheritance

Malignant hyperthermia susceptibility is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to increase the risk of a severe reaction to certain drugs used during surgery. In most cases, an affected person inherits the altered gene from a parent who is also at risk for the condition.

Other Names for This Condition

- Anesthesia related hyperthermia
- Hyperpyrexia, malignant

- Hyperthermia, malignant
- Malignant hyperpyrexia
- MHS

Additional Information & Resources

Genetic Testing Information

- Genetic Testing Registry: Malignant hyperthermia, susceptibility to, 1 (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C2930980/>)
- Genetic Testing Registry: Malignant hyperthermia, susceptibility to, 4 (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1838102/>)
- Genetic Testing Registry: Malignant hyperthermia, susceptibility to, 5 (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1866077/>)
- Genetic Testing Registry: Malignant hyperthermia, susceptibility to, 6 (<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1866076/>)

Genetic and Rare Diseases Information Center

- King-Denborough syndrome (<https://rarediseases.info.nih.gov/diseases/8433/index>)
- Malignant hyperthermia of anesthesia (<https://rarediseases.info.nih.gov/diseases/6964/index>)

Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD) (<https://rarediseases.org/>)

Clinical Trials

- ClinicalTrials.gov ([https://clinicaltrials.gov/search?cond=%22Malignant hyperthermia%22](https://clinicaltrials.gov/search?cond=%22Malignant%20hyperthermia%22))

Catalog of Genes and Diseases from OMIM

- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 1; MHS1 (<https://omim.org/entry/145600>)
- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 2 (<https://omim.org/entry/154275>)
- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3 (<https://omim.org/entry/154276>)

- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 5; MHS5 (<https://omim.org/entry/601887>)
- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 6 (<https://omim.org/entry/601888>)
- MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 4 (<https://omim.org/entry/600467>)

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28Malignant+Hyperthermia%5BMAJR%5D%29+AND+%28malignant+hyperthermia%5BTIAB%5D%29+AND+englih%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D>)

References

- Ellinas H, Albrecht MA. Malignant Hyperthermia Update. *Anesthesiol Clin*. 2020Mar; 38(1):165-181. doi: 10.1016/j.anclin.2019.10.010. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/32008650>)
- Kraeva N, Sapa A, Dowling JJ, Riazzi S. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. *Can J Anaesth*. 2017 Jul;64(7):736-743. doi:10.1007/s12630-017-0865-5. Epub 2017 Mar 21. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/28326467>)
- Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. *JAMA*. 2005 Jun 15;293(23):2918-24. doi: 10.1001/jama.293.23.2918. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/15956637>)
- Riazzi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. *Anesthesiology*. 2018 Jan;128(1):168-180. doi: 10.1097/ALN.0000000000001878. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/28902675>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726912/>)
- Riazzi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. *Can J Anaesth*. 2018 Jun;65(6):709-721. doi:10.1007/s12630-018-1108-0. Epub 2018 Mar 29. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/29600483>)
- Rosenberg H, Sambuughin N, Riazzi S, Dirksen R. Malignant Hyperthermia Susceptibility. 2003 Dec 19 [updated 2020 Jan 16]. In: Adam MP, Feldman J, Mirzazadeh GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews* (R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1146/> Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20301325>)
- Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S, Zorzato F. Ryanodine receptor 1 mutations, dysregulation of calcium

homeostasis and neuromuscular disorders. *Neuromuscul Disord*. 2005 Oct;15(9-10):577-87. doi:10.1016/j.nmd.2005.06.008. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/16084090>)

- Zaharieva IT, Sarkozy A, Munot P, Manzur A, O'Grady G, Rendu J, Malfatti E, Amthor H, Servais L, Urtizberea JA, Neto OA, Zanoteli E, Donkervoort S, Taylor J, Dixon J, Poke G, Foley AR, Holmes C, Williams G, Holder M, Yum S, Medne L, Quijano-Roy S, Romero NB, Faure J, Feng L, Bastaki L, Davis MR, Phadke R, Sewry CA, Bonnemann CG, Jungbluth H, Bachmann C, Treves S, Muntoni F. STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. *Hum Mutat*. 2018 Dec;39(12):1980-1994. doi:10.1002/humu.23635. Epub 2018 Oct 11. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/30168660>)
- Zvaritch E, Gillies R, Kraeva N, Richer M, Jungbluth H, Riazi S. Fatal awake malignant hyperthermia episodes in a family with malignant hyperthermia susceptibility: a case series. *Can J Anaesth*. 2019 May;66(5):540-545. doi:10.1007/s12630-019-01320-z. Epub 2019 Feb 19. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/30805902>)

Last updated March 1, 2020